Cerity Partners
APLS

Cerity Partners’s Apellis Pharmaceuticals APLS Stock Holding History

Cerity Partners’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23,971
Closed -$602K – 3243
2025
Q4 		$602K Sell
23,971
-104,139
-81% -$2.44M ﹤0.01% 1990
2025
Q3 		$2.9M Buy
128,110
+13,365
+12% +$312K ﹤0.01% 1111
2025
Q2 		$1.99M Buy
114,745
+60,301
+111% +$1.12M ﹤0.01% 1220
2025
Q1 		$1.19M Buy
54,444
+7,777
+17% +$215K ﹤0.01% 1353
2024
Q4 		$1.48M Buy
46,667
+15,286
+49% +$460K ﹤0.01% 1245
2024
Q3 		$905K Buy
31,381
+23,749
+311% +$880K ﹤0.01% 1447
2024
Q2 		$293K Buy
7,632
+3,351
+78% +$152K ﹤0.01% 1835
2024
Q1 		$252K Buy
+4,281
New +$273K ﹤0.01% 1969

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Cerity Partners's APLS Position: Q1 2026 in Review

Cerity Partners sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 23,971 shares — an estimated $602K sold.

Cerity Partners first reported a position in APLS in Q1 2024 and held it in 8 quarters. The position peaked at $2.9M in Q3 2025. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Cerity Partners reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Cerity Partners sold 23,971 Apellis Pharmaceuticals shares in Q1 2026, an estimated $602K.
  • Cerity Partners first reported a position in Apellis Pharmaceuticals in Q1 2024 and held it in 8 quarters.
  • Cerity Partners's Apellis Pharmaceuticals position peaked at $2.9M in Q3 2025.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.